Students for Life of America formally warned the Food and Drug Administration on Sept. 24 that it will sue under the Endangered Species Act unless the agency acts on the abortion pill mifepristone within 60 days. The anti-abortion group argues that the FDA broke federal wildlife law when it approved the drug in 2000 without consulting the U.S. Fish and Wildlife Service or the National Marine Fisheries Service, Fox News reported.
The notice asks the FDA to take specific actions, including environmental testing and pulling the drug from the market, The Hill reported. The 60-day window, which the wildlife law requires before most citizen lawsuits, runs to about Nov. 23.
For patients, nothing changes today. Mifepristone remains available under current FDA rules, including by mail, after the Supreme Court preserved access to the drug in May while Louisiana's legal challenge continues. Medication abortions accounted for nearly two-thirds of U.S. abortions in 2023, the most recent year with national data.
The timing was deliberate. The group filed hours before Dr. Heidi Overton, President Trump's nominee to lead the FDA, appeared for her Senate confirmation hearing.
The Legal Theory Behind the Notice
The Endangered Species Act requires federal agencies to consult wildlife regulators when an action may affect protected species or their habitats. Students for Life says the FDA skipped that step when it approved mifepristone and when it later allowed prescribing by telemedicine and delivery by mail. The group says it filed 11 citizen petitions before this notice.
The FDA has already rejected the argument once. On Jan. 15, 2025, the agency answered one petition by saying it was not required to consult wildlife agencies before approving the drug, Fox News reported.
"We expect these environmental concerns to be taken seriously," Students for Life President Kristan Hawkins told Fox News, adding that otherwise the group expects to see the FDA in court. She also pitched the issue beyond abortion politics: "But we all want clean drinking water." In a statement announcing the notice of intent to sue, the group said more than 1,500 protected species live in all 50 states.
The group claims more than 50 tons of abortion-related medical waste reach water systems each year. Environmental scientists dispute that claim, according to The Hill.
A notice of intent has no legal effect on its own. It does not alter the drug's approval, its label, or how pharmacies and telehealth services dispense it.
A Closer Look at the Water Evidence
The science offered so far is thin. Of six studies cited in the notice, four did not examine whether mifepristone was present in environmental water samples, according to Fox News.
The newest paper, published in Issues in Law & Medicine, reported anti-progesterone activity in water samples from three U.S. cities. That kind of test detects a biological effect, not the drug itself. The researchers said another compound could have produced the same result, and confirming mifepristone would generally require a chemistry method that identifies the specific molecule.
In plain terms, the evidence shows a possible signal in a small number of samples. It does not show that mifepristone is in tap water, at what level, or that any level found harms people or wildlife. The notice is a legal claim, not a regulatory finding, and no court has ruled on it.
Overton Hearing Puts the FDA's Next Move in Focus
At her hearing before the Senate health committee, Overton said mifepristone "has met the safety and efficacy determinations of the FDA," but she would not say how she would handle the drug if confirmed. Asked by Sen. Tammy Baldwin, D-Wis., whether its label should change, she pointed to the agency's ongoing internal safety review. "I can't prejudge the determination of a safety review that is currently ongoing," Overton said, according to Fierce Healthcare.
The FDA's review has been underway since 2025, and initial results are expected within weeks, The Hill reported from the hearing. While at the America First Policy Institute, Overton wrote that the FDA's decision to allow mail delivery of mifepristone was "dangerous to women," PBS NewsHour reported.
The people most affected by any future change include those seeking a medication abortion, patients who rely on telehealth because the nearest clinic is far away, and people managing a miscarriage, for whom mifepristone is also used.
Patients with a current prescription should follow their clinician's instructions and should not change their care because of this notice. Warning signs that need prompt attention include very heavy bleeding, a fever that does not go away, and severe abdominal pain. Anyone with those symptoms should contact a clinician right away or seek emergency care.
The FDA can respond within the 60-day window or let it pass. If the agency does not act, Students for Life says it will file suit in federal court. For now, this is a legal warning, not a ruling, and access is unchanged.
Key Questions Answered
What did Students for Life do? It filed a notice of intent to sue the FDA, claiming the agency violated the Endangered Species Act by approving mifepristone without consulting federal wildlife agencies.
When could a lawsuit be filed? The notice gives the FDA 60 days, which runs to about Nov. 23. The group says it will sue if the FDA does not act.
Is mifepristone still available? Yes. Current FDA rules remain in place, including mail delivery, after the Supreme Court preserved access in May.
Is mifepristone in drinking water? That has not been shown. The newest study detected anti-progesterone activity in some water samples but did not directly identify the drug, and the researchers said another compound could explain the result.
What did FDA nominee Heidi Overton say? She said the drug met FDA safety and efficacy standards but declined to prejudge the agency's ongoing safety review.
What should patients do now? Follow current prescriptions and clinician guidance. Seek urgent care for very heavy bleeding, persistent fever, or severe abdominal pain.
Published by Medicaldaily.com
